Kornimate/medical-research-clean huggingface dataset:
involuntary memories investigation in schizophrenia

Conditions: Schizophrenia

Summary: patients with schizophrenia suffer from autobiographical memory disorders. patients have difficulty to remember vividly personal past events when they are specifically asked for. indeed, this task requires a good executive functioning to retrieve precise information stored in long term memory. interestingly, executive functioning has been showed impaired in schizophrenia and studies showed that their autobiographical memory impairments were directed related to their executive dysfunction. yet, in daily life people remember more often autobiographical memories spontaneously, without trying voluntarily to recall them. in that case, the involuntary recall of personal past events is much less sustained by executive functioning. in this protocol the investigators would like to investigate and compare subjective characteristics of involuntary and voluntary autobiographical memories in order to highlight the role of executive dysfunction in patients' autobiographical memory impairments.


Eligibility criteria:
inclusion criteria: * - for patients only * male or female * age limits : 18-55 years old * under the protection of health insurance * who have signed up the consent form * schizophrenia or schizo-affective disorder according to the dsm-5 criteria (apa, 2013). * clinically stable for at least 2 months * patients under guardianship or curatorship need agreement of their legal representative * informed of the results of prior medical examination for controls only * male or female * age limits : 18-55 years old * under the protection of health insurance * who have sign up the consent form * recruited from the general population and matched on gender, age years of schooling * no psychiatric history (dsm-5) exclusion criteria: * for both patients and controls * current severe or unstable somatic illness * neurological history (brain injury \> 15 minutes loss of consciousness , epilepsia, brain surgery...) * current substance use disorder (dsm-5) * current major depressive disorder (cdss,bdi, hdrs) * mental retardation (iq \< 70, wais-4, f-nart) * history of general anesthesia 3 months prior to the experiment * pregnancy declared by the subject * breast feeding * current legal control * in emergency situation * included during exclusion period in another experiment * for controls only * taking of antipsychotic drugs for the 3 weeks prior to inclusion * under guardianship or curatorship
assessment of [18f]flt-pet imaging for diagnosis and prognosis of brain tumors

Conditions: Cancer; Brain Tumors

Summary: the primary objective of this study is to assess the efficacy of the radiopharmaceutical 3'-deoxy-3'-\[f-18\]fluorothymidine, \[f-18\]flt, a tracor of cell proliferation, using positron emission tomography (pet) imaging for the tumor diagnosis and prognosis in a group of 50 patients with different type of brain tumors.\[f-18\]flt pet imaging will be compared to the current used imaging techniques of mri, spectroscopy imaging, pet imaging using \[11c\]met tracer, immunohistochemical analysis and clinical parameters.


Eligibility criteria:
inclusion criteria: * adults aged between 18 and 70 years * must have operable grade ii, iii or iv glioma, recurrent high grade glioma or brain metastases * kps \>= 70% * must have the understanding and ability to sign an informed consent document * must have adequate liver and kidney function * be male or non-pregnant, non-lactating females * patients who are fertile must agree to use an effective method of contraception during participation in the study * the following laboratory results : absolute neutrophil count \>= 1500 cells/µl, platelet count \>= 100000 cells/µl, sgot \<= 2.5 x uln, serum creatinine \<= 1.5 x uln. exclusion criteria: * contraindication to surgery * concomitant radio-, chemo-, or immunotherapy * history of significant dementia * known diagnosis of human immunodeficiency virus (hiv) infection * patient with hepatitis b or c

Keywords: brain tumor [18f]flt [11c]met tep-imaging tumor cell proliferation
prospective evaluation of single cell mutations in a panel of known oncogenes in nsclc surgical specimens

Conditions: NSCLC

Summary: the goal of this observational study is to evaluate the feasibility of a single cell mutation research method in a panel of known oncogenes, using the tapestri method. tissue samples will be obtained after surgical treatment in patients with i-ii-iii stage nsclc.

nsclc is a particularly heterogeneous disease with different genetic alterations in oncogenes 'drivers', responsible for the development and progression of the disease. in most cases all these anomalies represent clonal mutations in all neoplastic cells. however, several sub-clonal genetic alterations were identified in some multi-regional sequencing studies, demonstrating an intra-tumor heterogeneity. tracing the clonal architecture of the disease and also the temporal order of the various mutations appearance, would bring two benefits: 1. prioritize the molecular targets 2. identify evolutionary trajectories associated with the outcome of therapies and survival, useful to stratify patients considering the likelihood and the duration of response for the bioinformatic data analyses will be used the tapestri missionbio pipeline. given the limited number of patients that can be included in the study (10 patients), no statistical analyzes will be performed. results will be presented thorugh narrative reports for each patients.

Eligibility criteria:
inclusion criteria: * age over 18 years old. * histological diagnosis of nsclc technically operable following multidisciplinary discussion * informed consent freely granted and obtained before the start of the study exclusion criteria: * age under 18 years old * unconfirmed nsclc histological diagnosis * medical treatment with neoadjuvant purposes * absence of informed consent
non-immunoglobulin e-mediated food allergies in children

Conditions: Non IgE Mediated Food Allergy; Food Protein-Induced Enteropathy; Food Protein-Induced Proctocolitis; Food Protein-Induced Enterocolitis Syndrome; Food Protein-induced Motility Disorders

Summary: non-ige-mediated gastrointestinal food allergies (non-ige-gifa) are an evolving web of clinical conditions characterized by subacute and/or chronic symptoms and include food protein-induced enterocolitis syndrome (fpies), food protein-induced enteropathy (fpe), food protein-induced allergic proctocolitis (fpiap), and food protein-induced allergic dysmotility disorders (gastroesophageal reflux disease (gerd), colic and constipation) (fpimd). despite the prevalence and clinical impact of these conditions, the pathogenesis as well as the natural history and the best management of these disorders are still poorly defined. these limitations could be responsible for diagnostic delays and errors, and suboptimal clinical management. we aim to evaluate clinical features, natural course and pathophysiology of non-ige-gifa in the pediatric age.


Eligibility criteria:
inclusion criteria: * subjects aged between 0-14 years * suggestive history of food allergy exclusion criteria: * age \>14 years- * chronic systemic diseases, * malignancy, * immunodeficiency, * infectious diseases, * autoimmune diseases, * inflammatory bowel diseases, * celiac disease, * metabolic and genetic diseases, * cystic fibrosis, * chronic pulmonary diseases, * gastrointestinal, respiratory, urinary tract and/or cardiovascular malformations, * neurologic and/or neuropsychiatric disorders, * gastrointestinal tract eosinophilic disorders, * use of immunomodulating drugs, steroids, pre-pro-synbiotics, antibiotics in the previous 4 months

Keywords: food allergy adverse food reactions immune tolerance atopy patch test atopic march oral food challenge food protein-induced enteropathy food protein-induced proctocolitis food protein-induced enterocolitis syndrome food protein-induced motility disorders
a clinical study of bemcentinib with standard of care chemoimmunotherapy in untreated advanced/metastatic non-small cell lung cancer patients with a mutation in the stk11 gene

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the primary purpose of this study is to determine the safety and tolerability of the combination of bemcentinib with chemo-immunotherapy (cit) to identify the recommended phase 2 dose (rp2d) when administered as first line (1l) treatment in participants with locally advanced (stage iiib/iiic) or metastatic (stage iv) non-squamous nsclc with no actionable mutations and to determine the anti-tumor activity of the combination of bemcentinib with cit when administered as 1l treatment in participants with locally advanced (stage iiib/iiic) or metastatic (stage iv) non-squamous nsclc with serine/threonine kinase 11 (stk11) mutation and no actionable mutations.


Eligibility criteria:
main inclusion criteria: * histologically-confirmed or cytologically confirmed diagnosis of advanced (stage iiib/iiic) or metastatic (stage iv) (ajcc edition 8) non-squamous nsclc not amenable to curative therapy, irrespective of pd-l1 status and without actionable mutations (phase 1b) targetable with first-line treatment. * histologically-confirmed or cytologically confirmed diagnosis of stage of advanced (stage iiib/iiic) or metastatic (stage iv) (ajcc, edition 8) non-squamous nsclc with stk11 mutation, not amenable to curative therapy, irrespective of pd-l1 status and without actionable mutations (phase 2a) targetable with first-line treatment. * have not received prior systemic treatment for their advanced/metastatic nsclc * have measurable disease per recist 1.1 as assessed by the investigator main exclusion criteria: * has received any prior chemotherapy or biological therapy for locally advanced (stage iiib/iiic) or metastatic (stage iv) adenocarcinoma of the lung * received radiation therapy within 2 weeks prior to starting study treatment or has not recovered (i.e. \<=grade 1 at baseline) from aes due to a previous radiation therapy * major surgery within 28 days prior to start of study treatment and failure to have recovered adequately from the complications of the surgery/intervention prior to the first dose of study treatment
patients with co-occurrence of anca vasculitis and sjögren syndrome

Conditions: ANCA Associated Vasculitis; Sjogren's Syndrome

Summary: anca vasculitis and sjögren syndrome are two rare diseases, and even more rarely associated. these two conditions have specific organ involvements, and specific follow-up. the investigators hypothesise that patients with co-occurrence of these two diseases may have a singular clinical course.


Eligibility criteria:
inclusion criteria: * diagnosis of anca vasculitis based on clinical, immunological and histopathological features. * diagnosis of sjögren syndrom based on acr/eular 2016 criteria. exclusion criteria: * age \< 18 years * insuffisant data during follow-up

Keywords: overlap syndrom
cryotherapy -beats-rf ablation trial

Conditions: Barrett's Esophagus With Persistent Dysplasia or; Early Esophageal Adenocarcinoma Post Radio Frequency Ablation

Summary: the purpose of this study is to determine whether cryotherapy is effective in the treatment of persistent high grade dysplasia (hgd) or early esophageal adenocarcinoma (imca) in patients who have not responded to radiofrequency ablation (rfa).


Eligibility criteria:
inclusion criteria: * age \> 18 years old * able to provide informed consent * patients with unifocal or multifocal be with hgd or imca who have failed at least 2 serial rfa therapy. * patients who refused esophagectomy or deemed inoperable or whose be dysplasia is not amenable to endoscopic mucosal resection (emr) treatment alone due to: (1) extensive multifocal lesions (2) severe coagulopathy or any medical condition deemed high risk for emr (3) patient refuses emr * patients with a nodular be lesions may undergo clinically-indicated emr and still be eligible for enrollment as long as they have be-hgd lesion/s that are still candidate for ablative treatment exclusion criteria: * age younger than 18 years old * life expectancy less than 12 months * pregnancy * presence of esophageal varices * esophageal stricture precluding passage of an endoscope and suction tubing * any procedure that has impeded normal gastric emptying or limited gastric volume distention, including but not limited to gastric bypass, stomach stapling, gastrojejunostomy or any disease state has significantly reduced the elasticity in the gi tract (e.g. marfan's syndrome, scleroderma or any connective tissue disease) * esophageal cancer (t2 and above)

Keywords: barrett's esophagus early esophageal adenocarcinoma radio frequency ablation cryotherapy
evaluation of early identification of cognitive side effects of immunotherapy

Conditions: Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm

Summary: this clinical trial evaluates the use of a tool kit, stress, affect, language and speech analysis (salsa), for early identification of cognitive side effects of immunotherapy compared to the standard of care assessment.

primary objectives: i. to investigate the use of a toolkit for automated administration and scoring of cognitive tests (stress, language and speech analysis, or salsa) in adult cancer patients who are treated with commercial chimeric antigen receptor t cell therapy (car-t) products at university of minnesota and are at risk of developing immune effector cell-associated neurotoxicity syndrome (icans). outline: this is an observational study. patients complete salsa assessment and ice assessments on study. patients also have their medical records reviewed on study.

Eligibility criteria:
inclusion criteria: * \* ≥ 18 years of age at initiation of therapy * planning to undergo inpatient car-t therapy for primary malignancy * fluent in english (written or spoken) exclusion criteria: * \* subjects with speech or hearing impediment that would make them unable to be assessed with salsa * subjects with diagnosed cognitive impairment prior to car-t therapy * unwilling or unable to sign voluntary written consent
echocardiography and peak endocardial acceleration (pea) measurements in cardiac resynchronization therapy (crt)

Conditions: Congestive Heart Failure

Summary: this study used an external endocardial acceleration sensor (sonr sensor), placed on the patient's chest, to time the closure of aortic and mitral valves, and compared its performance with echocardiography.


Eligibility criteria:
inclusion criteria: * every patient coming in the participating centers for an echocardiographic exam and implanted with a pacemaker or an implantable cardioverter defibrillator (icd) can be included in the study. exclusion criteria: * inability to understand the patient information sheet. * minor patient or pregnant woman.

Keywords: heart failure - congestive cardiovascular imaging agents/techniques] echocardiography other diagnostic testing other treatment recipients of cardiac resynchronization therapy systems
unilateral versus bilateral stents for bismuth type ii and iii malignant hilar strictures

Conditions: Cholangiocarcinoma

Summary: the aim of the present study was to compare the effect of unilateral versus bilateral stenting in patients with malignant hilar obstruction.

cholangiocarcinoma accounts for 3% of all gastrointestinal cancers and is the second commonest primary liver cancer. however only a few patients are suitable for surgical resection and therefore endoscopic biliary drainage is the most used palliative treatment modality for malignant hilar stricture. however, whether one or two stents can benefit the patients most is still to be defined. numerous retrospective case series reached different conclusion, till now, only one randomized trial compared the effect of unilateral versus bilateral stenting in patients with malignant hilar obstruction, nonetheless, nearly one third of the patients had bismuth type i stricture, and one stent is enough for drainage in this situation, therefore, the best drainage strategy for patients with bismuth type ii or bismuth type iii malignant hilar obstruction is unknown. the aim of the present study was to compare the effect of unilateral versus bilateral stenting in patients with bismuth type ii or iii malignant hilar obstruction.

Eligibility criteria:
inclusion criteria: * consecutive untreated patients with biliary obstruction (bismuth type ii, iii) at the hilum due to primary cholangiocarcinoma, gallbladder cancer, or periportal lymph node metastases. diagnosis is based on us, ct, and mrcp. * histologic or cytologic confirmation of malignancy is established by percutaneous biopsy (us- or ct-guided) or by endoscopic tissue sampling, endoscopic brushing. or the diagnosis is based on typical features on imaging and the expected clinical outcome during follow-up. * all patients were considered unsuitable for resection on the basis of general medical condition and/or tumor extent. * full and informed consent is obtained. exclusion criteria: * refuse to participate in this study. * refuse to provide informed consent. * refuse to be placed with plastic stents. * physically unfit for endoscopic treatment.

Keywords: ercp cholangiocarcinoma hilar stricture
evaluation of early administration of levetiracetam in the prevention and treatment encephalopathy in septic shock: randomized, double-blind, placebo-controlled trial

Conditions: Septic Shock

Summary: sepsis-associated encephalopathy is associated with high mortality rates and long-term neuropsychiatric disorders. currently, there is no specific treatment for sepsis-associated encephalopathy. levetiracetam, a broad-spectrum antiepileptic widely used in intensive care units, has neuroprotective properties. we propose the kiss study, a multicenter, prospective, randomized, double-blind trial with two arms, evaluating the effect of levetiracetam treatment for seven days during septic shock on the occurrence and duration of sepsis-associated encephalopathy.


Eligibility criteria:
inclusion criteria : * aged 18 years or older * hospitalized in intensive care for less than 96 hours * presenting with septic shock evolving for less than 24 hours defined by: 1. clinically or microbiologically documented infection and 2. sofa score ≥ 2 or an increase in sofa score ≥ 2 points if organ dysfunction was present before the infection and 3. need for vasopressor administration to maintain a mean arterial pressure ≥ 65mmhg and 4. lactate level \> 2mmol/l (18mg/dl) despite adequate fluid resuscitation * patient's consent, their next of kin consent, or emergency inclusion non inclusion criteria : * chronic long-term antiepileptic treatment upon admission or patient with uncontrolled seizures * chronic or progressive central neurological pathologies of traumatic, inflammatory, vascular, infectious, neoplastic, or degenerative origin, defined by cognitive impairments preventing independent living or an iqcode score \> 4.5 * patient with moderate to severe dementia * patient with psychiatric history and/or suicide attempts * severe head trauma within the past 3 months * patients with limitations on active therapies or for whom therapeutic commitment is not maximal * patient presenting a prolonged qtc interval on ecg and/or at risk of cardiovascular disease * concomitant treatment with methotrexate during the administration of the investigational treatment * allergy to levetiracetam * minor patients * ongoing pregnancy (blood or urinary βhcg) * breastfeeding women * patients under guardianship or trusteeship * non-affiliation with social security or cmu * participation in another interventional trial with a drug that may interact with levetiracetam or may impact the evaluation of kiss trial outcomes. in case of doubt, please contact the trial's coordinating investigator.
the role of reactive oxygen species in ischaemia-reperfusion injury of the transplanted kidney

Conditions: Kidney Transplantation

Summary: measurement of reactive oxygen species production and antioxidant system status before and directly after reperfusion of the transplanted kidney and influence of oxidant stress on kidney function in 2 and 6 weeks.

oxidative stress is one of the most important factors in ischaemia-reperfusion injury to the transplanted organ. in kidney transplant recipients following factors were measured: glutathione level, activities of glutathione peroxidase (gsh-px), catalase (cat) and superoxide dismutase (sod) and superoxide anion production by granulocytes in whole blood without and after the stimulation with zymosan. blood was sampled from peripheral vein (before reperfusion) and directly from renal vein (5 and 15 minutes after reperfusion). transplanted kidney function was evaluated by the incidence and length of delayed graft function and serum creatinine level in 2 and 6 weeks after transplantation.

Eligibility criteria:
inclusion criteria: * consecutive patients accepted for and undergoing cadaveric kidney transplantation exclusion criteria: * no informed consent

Keywords: kidney transplantation reperfusion injury
pilot study to assess cat-2003 in patients with chylomicronemia

Conditions: Lipoprotein Lipase Deficiency, Familial; Hyperlipoproteinemia Type I; Chylomicronemia, Familial; Hypertriglyceridemia

Summary: the purpose of this study is to assess safety and efficacy of cat-2003 in patients with chylomicronemia. the study will evaluate the effects of cat-2003 on fasting total and chylomicron triglyceride levels, as well as postprandial total and chylomicron triglyceride clearance. this is a single-blind study. all patients will receive placebo for 1 week, and cat-2003 for 12 weeks during the 13 week treatment period.


Eligibility criteria:
key inclusion criteria: * familial chylomicronemia (fasting triglycerides ≥ 880 mg/dl at screening and documented history of plasma post-heparin ldl activity \< 20% of normal or genetic confirmation of homozygosity or compound heterozygosity for loss-of-function mutations in familial chylomicronemia-causing genes) or * non-familial chylomicronemia (fasting triglycerides ≥ 440 mg/dl at screening and documented history of fasting triglycerides ≥ 880 mg/dl) key exclusion criteria: * history of any major cardiovascular event within 6 months of screening * type i diabetes mellitus or use of insulin * history of pancreatitis within 3 month of screening